Alpha 2.0
Login Register
» Articles » PMID: 22275981

Gemcitabine-induced Progressive and Sustained Tumour Response in a Patient with Multi-drug Resistant Uterine Leiomyosarcoma

Overview
Journal Ecancermedicalscience
Specialty Oncology
Date 2012 Jan 26
PMID 22275981
Authors
T De Pas
G Spitaleri
P D Vigna
F Toffalorio
G Curigliano
A Gambino
S Boselli
C Catania
F de Braud
Affiliations
Soon will be listed here.
Abstract

Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.

Case Report: we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.

Conclusions: GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.

References
1.
Bay J, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S . Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006; 119(3):706-11. DOI: 10.1002/ijc.21867. View
2.
Maki R . Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007; 12(8):999-1006. DOI: 10.1634/theoncologist.12-8-999. View
3.
Look K, Sandler A, Blessing J, Lucci 3rd J, Rose P . Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol. 2004; 92(2):644-7. DOI: 10.1016/j.ygyno.2003.11.023. View
4.
Maki R, Wathen J, Patel S, Priebat D, Okuno S, Samuels B . Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007; 25(19):2755-63. DOI: 10.1200/JCO.2006.10.4117. View
5.
Hensley M, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C . Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20(12):2824-31. DOI: 10.1200/JCO.2002.11.050. View